1 15 15 11 3a

2a Sydney M. Evans, VMD

1 19 19 31 19 65 19 19 49 31 31 19 19 19 19 19 45

19 19 19 1 1 1 1 2d

Emeritus Professor of Radiation Oncology

74 Department: Radiation Oncology

11 13

1 1 5

1 18

Contact Information

3c 187 John Morgan Building
1a 3620 Hamilton Walk
5b
Philadelphia, PA 19104 c0
Office: 215-898-0074
Email: sydevans@pennmedicine.upenn.edu

5 9 e

Links

9 12

Education

3e BS (Pre-Veterinary Medicine) 5f
Rutgers University, Douglas College, 1973
3b VMD (Veterinary Medicine) 77
University of Pennsylvania, School of Veterinary Medicine , 1977
43 MS (Comparative Medical Sciences) 76
University of Pennsylvania, School of Veterinary Medicine , 1986

1 5

1 1 1 2b

Description of Research Expertise

KEYWORDS:
89 Measuring hypoxia in vivo; Animal Models of human disease; Cancer physiology, proliferation; Cancer physiology; tumor vasculature
8
1b RESEARCH INTERESTS:
689 The primary emphasis of the work in the Evans laboratory is to determine causes of treatment resistance in human cancer. The treatment resistance factor that is emphasized is hypoxia. The presence, level and distribution of hypoxia is measured using a 2-nitroimidazole agent, EF5, developed by Dr. Cameron Koch, also from the Department of Radiation Oncology, at PENN. EF5 can be used for in vitro or in vivo studies. The majority of studies in the Evans laboratory involve in vivo studies in animals or humans. Given intravenously, this agent is reduced and bound in hypoxic cells. The adducts thus formed are recognized by a specific fluorescent monoclonal antibody. Tumor tissue or cells are studied either using immunohistochemistry or flow cytometry. This fluorescence can be measured and converted into tissue pO2 based upon previously published in vitro studies. We have performed studies using EF5 in animal models of cancer and, since 1998 have been performing clinical trials to evaluate the presence and level of hypoxia in various human cancers. We are currently funded by the NIH to perform studies in human brain tumors, head and neck cancers, sarcomas, cervix, and intraperitoneal cancers. We have shown that hypoxia, as measured by EF5 binding correlates to the level of tumor aggression in glial brain tumors, soft tissue sarcomas and head/neck squamous cell cancers. We have recently been able to produce [F-18]-EF5, which can be analyzed with positron emission tomography, PET imaging. Grants to study EF5 binding, with both immunohistochemical and PET endpoints in patients with brain tumors and head and neck cancer have been funded by the NIH.
8
5

1 2b

Description of Clinical Expertise

Measuring hypoxia and predicting treatment response in brain tumors
4b Measuring hypoxia and predicting treatment responsein cervix cancer
63 Measuring hypoxia and predicting treatment responsein head and neck squamous cell carcinoma
5d Measuring hypoxia and predicting treatment responsein carcinomatosis and sarcomatosis
4d Measuring hypoxia and predicting treatment responsein pleural cancers
50 Measuring hypoxia and predicting treatment response in soft tissue sarcomas

1 28

Description of Other Expertise

Mentoring junior faculty
14 Mentoring women

1 1 1f

Selected Publications

100 Evans SM, Putt M, Yang XY, Lustig RA, Martinez-Lage M, Williams D, Desai A, Wolf R, Brem S, Koch CJ. : Initial evidence that blood-borne microvesicles are biomarkers for recurrence and survival in newly diagnosed glioblastoma patients. 48 Journal of Neuro-Oncology 127(2) : 391-400, Apr 2016
ff Lao Z, Kelly CJ, Yang XY, Jenkins WT, Toorens E, Ganguly T, Evans SM, Koch CJ. : Improved Methods to Generate Spheroid Cultures from Tumor Cells, Tumor Cells & Fibroblasts or Tumor-Fragments: Microenvironment, Microvesicles and miRNA. 3b PLoS One 10(7) : e0133895, Jul 24 2015
1ca Morgans AK, van Bommel AC, Stowell C, Abrahm JL, Basch E, Bekelman JE, Berry DL, Bossi A, Davis ID, de Reijke TM, Denis LJ, Evans SM, Fleshner NE, George DJ, Kiefert J, Lin DW, Matthew AG, McDermott R, Payne H, Roos IA, Schrag D, Steuber T, Tombal B, van Basten JP, van der Hoeven JJ, Penson DF : Development of a Standardized Set of Patient-centered Outcomes for Advanced Prostate Cancer: An International Effort for a Unified Approach. 3c European Urology 68(5) : 891-8, Nov 2015
71 Koch CJ, Evans SM : Pharmacokinetic and pharmacodynamic modifiers of EF5 uptake and binding. 45 Journal of Nuclear Medicine 56(4) : 653, Apr 2015
5f Koch CJ, Evans SM : Optimizing Hypoxia Detection and Treatment Strategies. 49 Seminars in Nuclear Medicine 45(2) : 163-76, Mar 2015
fb Koch CJ, Lustig RA, Yang XY, Jenkins WT, Wolf RL, Martinez-Lage M, Desai A, Williams D, Evans SM : Microvesicles as a Biomarker for Tumor Progression versus Treatment Effect in Radiation/Temozolomide-Treated Glioblastoma Patients. 41 Translational Oncology 7(6) : 752-8, Dec 2014
cc Koch CJ, Jenkins WT, Jenkins KW, Yang XY, Shuman AL, Pickup S, Riehl1 CR, Paudya R, Poptani H, Evans SM : Mechanisms of Blood Flow and Hypoxia Production in Rat 9L Epigastric Tumors 4c Tumor Microenvironment and Therapy 1(1) : 1-13, Jan 2013
c5 Sood N, Jenkins WT, Yang XY, Shah NN, Katz JS, Koch CJ, Frail PR, Therien MJ, Hammer DA, Evans SM. : Biodegradable polymersomes for the delivery of Gemcitabine to Panc-1 cells. 41 Journal of Pharmaceutics 2013 : 932797, 2013
19 Lilie L Lin, LL 13 Antti Silvoniemi 10 James B Stubbs f Ramesh Rengan 10 Sami Suilamo c Olof Solin 12 Chaitanya Divgi e Olli Eskola 15 Jonathan M. Sorger 14 Michael G. Stabin 12 Alexander Kachur 11 Stephen M. Hahn 11 Tove Grönroos 12 Sarita Forsback 11 Sydney M Evans 11 Cameron J. Koch 78 Heikki Minn : Radiation Dosimetry and Biodistribution of the Hypoxia Tracer 18F-EF5 in Oncologic Patients. 54 Cancer Biotherapy & Radiopharmaceuticals 27(7) : 412-9, Sep 2012
11e Marotta D, Karar J, Jenkins WT, Kumanova M, Tobias JW, Baldwin D, Hadjigeorgiou A, Alexiou P, Evans SM, Alarcon R, Maity A, Koch CJ, Koumenis C : In vivo profiling of hypoxic gene expression in gliomas using the hypoxia marker EF5 and laser-capture microdissection. 3f Cancer Research 71(3) : 779-89, Feb 2011

1 1 19 1b

11 15 11 15 25 11 11 11 18